AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Alum Compounds: Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.South Africa: A republic in southern Africa, the southernmost part of Africa. It has three capitals: Pretoria (administrative), Cape Town (legislative), and Bloemfontein (judicial). Officially the Republic of South Africa since 1960, it was called the Union of South Africa 1910-1960.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.LondonNational Institute of Allergy and Infectious Diseases (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. It was established in 1948.San FranciscoNational Institute of Dental and Craniofacial Research (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. It seeks to improve oral, dental and craniofacial health through research, research training, and the dissemination of health information by conducting and supporting basic and clinical research. It was established in 1948 as the National Institute of Dental Research and re-named in 1998 as the National Institute of Dental and Craniofacial Research.HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.vif Gene Products, Human Immunodeficiency Virus: Proteins encoded by the VIF GENES of the HUMAN IMMUNODEFICIENCY VIRUS.Anti-HIV Agents: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.Saudi ArabiaMuntjacs: A genus, Muntiacus, of the deer family (Cervidae) comprising six species living in China, Tibet, Nepal, India, the Malay Peninsula, and neighboring island countries. They are usually found in forests and areas of dense vegetation, usually not far from water. They emit a deep barklike sound which gives them the name "barking deer." If they sense a predator they will "bark" for an hour or more. They are hunted for their meat and skins; they thrive in captivity and are found in many zoos. The Indian muntjac is believed to have the lowest chromosome number in mammals and cell lines derived from them figure widely in chromosome and DNA studies. (From Walker's Mammals of the World, 5th ed., p1366)Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Economics, Pharmaceutical: Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))Pharmaceutical Preparations: Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.Advertising as Topic: The act or practice of calling public attention to a product, service, need, etc., especially by paid announcements in newspapers, magazines, on radio, or on television. (Random House Unabridged Dictionary, 2d ed)United StatesVaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Meningitis, Bacterial: Bacterial infections of the leptomeninges and subarachnoid space, frequently involving the cerebral cortex, cranial nerves, cerebral blood vessels, spinal cord, and nerve roots.Meningitis: Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)Motion Pictures as Topic: The art, technique, or business of producing motion pictures for entertainment, propaganda, or instruction.Meningitis, Pneumococcal: An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)CaliforniaMeningitis, Aseptic: A syndrome characterized by headache, neck stiffness, low grade fever, and CSF lymphocytic pleocytosis in the absence of an acute bacterial pathogen. Viral meningitis is the most frequent cause although MYCOPLASMA INFECTIONS; RICKETTSIA INFECTIONS; diagnostic or therapeutic procedures; NEOPLASTIC PROCESSES; septic perimeningeal foci; and other conditions may result in this syndrome. (From Adams et al., Principles of Neurology, 6th ed, p745)Famous PersonsMeningitis, Viral: Viral infections of the leptomeninges and subarachnoid space. TOGAVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; RUBELLA; BUNYAVIRIDAE INFECTIONS; ORBIVIRUS infections; PICORNAVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RHABDOVIRIDAE INFECTIONS; ARENAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; JC VIRUS infections; and RETROVIRIDAE INFECTIONS may cause this form of meningitis. Clinical manifestations include fever, headache, neck pain, vomiting, PHOTOPHOBIA, and signs of meningeal irritation. (From Joynt, Clinical Neurology, 1996, Ch26, pp1-3)Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Meningitis, Haemophilus: Infections of the nervous system caused by bacteria of the genus HAEMOPHILUS, and marked by prominent inflammation of the MENINGES. HAEMOPHILUS INFLUENZAE TYPE B is the most common causative organism. The condition primarily affects children under 6 years of age but may occur in adults.Laughter: An involuntary expression of merriment and pleasure; it includes the patterned motor responses as well as the inarticulate vocalization.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Vaccines, Combined: Two or more vaccines in a single dosage form.RussiaBacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. (1/1614)

The proliferative responses to a series of peptides constituting the human immunodeficiency virus type 1 (HIV-1) gp120 sequence were evaluated in 19 HIV-1-infected rgp160 vaccine recipients, 17 HIV-1-infected rgp120 vaccine recipients, 15 HIV-1-infected placebo recipients, and 18 HIV-1-uninfected controls. Many regions of the gp120 molecule were found to contribute proliferative epitopes, although there were clearly regions of relative dominance and silence. Vaccine recipients tended to have broader, more robust, and more frequent peptide recognition than the placebo recipients. Despite the considerable variability in the pattern of peptide recognition among individuals, there was a striking similarity between the rgp160 and rgp120 vaccinee groups as a whole. Low-risk HIV-1-uninfected individuals may react to a few peptides within the gp120 sequence as well, despite a lack of significant response to the whole gp120 protein.  (+info)

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. (2/1614)

The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-gamma) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the fourth immunization, and the rgp120/MF59 group generated both IFN-gamma and interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-gamma (type 1-like), and IL-4 responses that peaked after the second immunization. To determine which type of immune responses correlated with protection from infection, all animals were challenged intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were completely protected from infection. In other subunit vaccinees there was evidence by multiple assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of potent type 1- as well as type 2-like T-helper responses induced the most-effective immunity.  (+info)

Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. (3/1614)

The potential roles of adhesion molecules in the expansion of T cell-mediated immune responses in the periphery were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the adhesion molecules intracellular adhesion molecule-1 (ICAM-1), lymphocyte function associated-3 (LFA-3), and vascular cell adhesion molecule-1 (VCAM-1) along with DNA immunogens, and we analyzed the resulting antigen-specific immune responses. We observed that antigen-specific T-cell responses can be enhanced by the coexpression of DNA immunogen and adhesion molecules ICAM-1 and LFA-3. Coexpression of ICAM-1 or LFA-3 molecules along with DNA immunogens resulted in a significant enhancement of T-helper cell proliferative responses. In addition, coimmunization with pCICAM-1 (and more moderately with pCLFA-3) resulted in a dramatic enhancement of CD8-restricted cytotoxic T-lymphocyte responses. Although VCAM-1 and ICAM-1 are similar in size, VCAM-1 coimmunization did not have any measurable effect on cell-mediated responses. These results suggest that ICAM-1 and LFA-3 provide direct T-cell costimulation. These observations are further supported by the finding that coinjection with ICAM-1 dramatically enhanced the level of interferon-gamma (IFN-gamma) and beta-chemokines macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and regulated on activation normal T-cell expression and secreted (RANTES) produced by stimulated T cells. Through comparative studies, we observed that ICAM-1/LFA-1 T-cell costimulatory pathways are independent of CD86/CD28 pathways and that they may synergistically expand T-cell responses in vivo.  (+info)

Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. (4/1614)

Inoculation of chimpanzees with human immunodeficiency virus type 1 (HIV-1) has been used as a model system to define mechanisms of pathogenesis and to test protective efficacy of candidate HIV-1 vaccines. In most of these studies, the animals were inoculated intravenously. However, because HIV-1 is transmitted primarily across mucosal surfaces, future evaluations of vaccines should employ mucosal routes for administering infectious virus to immunized animals. To develop a model of rectal transmission of HIV-1, chimpanzees were exposed without trauma to 4 different HIV-1 strains at doses ranging from 200 to 10,000 TCIDs. Infection, characterized by seroconversion and repeated isolation of virus from lymphocytes, was established in 1 of 5 animals. This animal was sequentially inoculated with a subtype B and then an E strain and was infected with both strains. The results show that rectal exposure of adult chimpanzees to cell-free HIV-1 was not an efficient mode of transmission in this cohort.  (+info)

Mucosal vaccination strategies for women. (5/1614)

Women were immunized orally, rectally, or vaginally with a recombinant cholera toxin B-containing vaccine to determine which of these mucosal immunization routes generate the greatest levels of antibody in the female genital tract and rectum. ELISA was used to measure concentrations of cholera toxin B-specific IgA and IgG antibody in serum and secretions before and after three immunizations. Each immunization route similarly increased specific IgG in serum and specific IgA in saliva. Only the vaginal route increased IgA antibodies in genital tract secretions and could be shown to induce a local IgG response. However, vaginal immunization failed to produce antibody in the rectum. In a similar fashion, rectal immunization elicited highest concentrations of locally derived IgA and IgG antibody in the rectum but was ineffective for generating antibody in the genital tract. The data suggest that local immunization may induce the greatest immune responses in the female genital tract and rectum of humans.  (+info)

Detection of intracellular antigen-specific cytokines in human T cell populations. (6/1614)

Determination of antigen-specific cytokine responses of T lymphocytes after vaccination is made difficult by the low frequency of responder cells. In order to detect these responses, the profile of intracellular cytokines was analyzed using flow cytometry after antigenic expansion. Peripheral blood mononuclear cells were stimulated with antigens for 5 days, further expanded with interleukin (IL)-2, and then restimulated on day 10. Cytokine production was detected by intracellular staining with monoclonal antibodies after saponin-based permeabilization. Influenza expansion resulted in specific interferon-gamma (IFN-gamma) production of 6%-20%, with less IL-4 production (0%-2%). Tetanus toxoid resulted in even greater production. IL-4 and IFN-gamma were produced mainly by memory cells of the CD45RO+ phenotype. IFN-gamma production was contributed by both CD4 and CD8 populations. These methods were then applied to a clinical trial of a candidate human immunodeficiency virus type 1 vaccine. Antigen-specific increases in IFN-gamma were measured, which corresponded to antibody production, lymphoproliferation, and skin testing.  (+info)

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. (7/1614)

The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study in animal models because most primary HIV-1 strains do not infect nonhuman primates. Using a chimeric simian/human immunodeficiency virus (SHIV) based on the envelope of a primary isolate (HIV-89.6), we performed passive-transfer experiments in rhesus macaques to study the role of anti-envelope antibodies in protection. Based on prior in vitro data showing neutralization synergy by antibody combinations, we evaluated HIV immune globulin (HIVIG), and human monoclonal antibodies (MAbs) 2F5 and 2G12 given alone, compared with the double combination 2F5/2G12 and the triple combination HIVIG/2F5/2G12. Antibodies were administered 24 h prior to intravenous challenge with the pathogenic SHIV-89.6PD. Six control monkeys displayed high plasma viremia, rapid CD4(+)-cell decline, and clinical AIDS within 14 weeks. Of six animals given HIVIG/2F5/2G12, three were completely protected; the remaining three animals became SHIV infected but displayed reduced plasma viremia and near normal CD4(+)-cell counts. One of three monkeys given 2F5/2G12 exhibited only transient evidence of infection; the other two had marked reductions in viral load. All monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed high-level plasma viremia. However, compared to controls, monkeys that received HIVIG or MAb 2G12 displayed a less profound drop in CD4(+) T cells and a more benign clinical course. These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease.  (+info)

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. (8/1614)

Overcoming preexisting immunity to vaccinia virus in the adult population is a key requirement for development of otherwise potent recombinant vaccinia vaccines. Based on our observation that s.c. immunization with vaccinia induces cellular and antibody immunity to vaccinia only in systemic lymphoid tissue and not in mucosal sites, we hypothesized that the mucosal immune system remains naive to vaccinia and therefore amenable to immunization with recombinant vaccinia vectors despite earlier vaccinia exposure. We show that mucosal immunization of vaccinia-immune BALB/c mice with recombinant vaccinia expressing HIV gp160 induced specific serum antibody and strong HIV-specific cytotoxic T lymphocyte responses. These responses occurred not only in mucosal but also in systemic lymphoid tissue, whereas systemic immunization was ineffective under these circumstances. In this context, intrarectal immunization was more effective than intranasal immunization. Boosting with a second dose of recombinant vaccinia was also more effective via the mucosal route. The systemic HIV-specific cytotoxic T lymphocyte response was enhanced by coadministration of IL-12 at the mucosal site. These results also demonstrate the independent compartmentalization of the mucosal versus systemic immune systems and the asymmetric trafficking of lymphocytes between them. This approach to circumvent previous vaccinia immunity may be useful for induction of protective immunity against infectious diseases and cancer in the sizable populations with preexisting immunity to vaccinia from smallpox vaccination.  (+info)

*DNA vaccination

... such as those with AIDS). While killed vaccines do not have this risk, they cannot generate specific killer T cell responses ... Second generation vaccines were developed to reduce the risks from live vaccines. These are subunit vaccines, consisting of ... First generation vaccines are whole-organism vaccines - either live and weakened, or killed forms. Live, attenuated vaccines, ... A veterinary DNA vaccine to protect horses from West Nile virus has been approved. DNA vaccines elicit the best immune response ...

*Immunologic adjuvant

MF59 is an 'oil [squalene] in water' adjuvant used in some human vaccines. An increasing number of vaccines with squalene and ... The word "adjuvant" comes from the Latin word adiuvare, meaning to help or aid. "An immunologic adjuvant is defined as any ... "Guideline on Adjuvants in Vaccines for Human Use" (PDF). The European Medicines Agency. Retrieved 8 May 2013. DNA Vaccines: ... PMID 26344622 PMC 4494261/ Baylor N, Egan W, Richman P (2002). "Aluminum salts in vaccines--US perspective". Vaccine. 20 (Suppl ...

*Gladstone Institutes

Using iPS technology to create a new model for testing a vaccine for HIV/AIDS. Translational Research The Gladstone Center for ... Robert M. Grant-Led the global study, referred to as iPrEx, which in 2010 showed how an existing HIV/AIDS medication called ... Investigating the mechanisms by which HIV infects and kills lymphoid CD4 T-cells, the fundamental cause of AIDS, and the role ... Specifically, these findings could open the door to an entirely new class of "anti-AIDS" therapies that act by targeting the ...

*AIDS Vaccine 200

Action Cycling Atlanta/AIDS Vaccine 200 AIDS Vaccine 200 AV 200 on YouTube AIDS Vaccine 200 - AV 200 on Facebook AIDS Vaccine ... through its Action Cycling 200 and AIDS Vaccine 200 rides has donated a total of $2,781,090 for AIDS vaccine research and AIDS- ... The majority of these funds ($557,000) has gone towards AIDS vaccine research at Emory Vaccine Center. The ride also ... 2.4 million to the Emory Vaccine Center, one of the world's leading vaccine research centers working to find an HIV vaccine. ...

*World AIDS Vaccine Day

International AIDS Vaccine Initiative - India Website Kenya AIDS Vaccine Initiative (KAVI) The South Africa AIDS Vaccine ... World AIDS Vaccine Day, also known as HIV Vaccine Awareness Day, is observed annually on May 18. HIV vaccine advocates mark the ... preventive HIV vaccine can limit and eventually eliminate the threat of AIDS." The first World AIDS Vaccine Day was observed on ... South African AIDS Vaccine Initiative (SAAVI) World AIDS Day Bill Clinton's commencement speech at Morgan State University AIDS ...

*AIDS Vaccine Bike Trek

... 2016 Charlottesville to Washington AIDS Vaccine Bike Trek 2017 Burlington to Portland AIDS Vaccine Bike ... Charity Treks, Inc has organized several AIDS Vaccine Bike Treks in North America: Montreal to Maine AIDS Vaccine Bike Trek ... Montreal to Boston AIDS Vaccine Bike Trek 2004, August 17-21 (Raised $118,150) Montreal to Boston AIDS Vaccine Bike Trek 2005, ... Montreal to Portland AIDS Vaccine Bike Trek 2007, August 14-18 (Raised $124,075) Burlington to Portland AIDS Vaccine Bike Trek ...

*AIDS Vaccine Advocacy Coalition

... the International AIDS Vaccine Initiative, Until There's a Cure Foundation, Broadway Cares/Equity Fights AIDS, the Gill ... AVAC works to provide independent analysis, policy advocacy, public education and mobilisation to enhance AIDS vaccine research ... "AIDS Vaccine Advocacy Coalition(AVAC)". Archived from the original on 2011-07-20. ... and consumer-based organization working to accelerate ethical development and delivery of AIDS vaccines and other HIV ...

*International AIDS Vaccine Initiative

... TechImpact @ Yale, 3(1), 1-2. Cohen, Jon (2009). Potent Antibodies Spark Vaccine Hopes. ... The International AIDS Vaccine Initiative (known as IAVI) is a global not-for-profit, public-private partnership working to ... It also partners with civil society organizations and other entities to advocate jointly for the development of AIDS vaccines, ... To address major obstacles in AIDS vaccine development, IAVI partners with HIV researchers from around the world. Its ...

*Collaboration for AIDS Vaccine Discovery

The Collaboration for AIDS Vaccine Discovery (CAVD) is an international network of scientists, research organizations, and ... The CAVD was founded in 2006 when the Bill & Melinda Gates Foundation donated $287 million USD to promote HIV vaccine research ... The CAVD itself supports the Global HIV Vaccine Enterprise. The network comprises many individual institutions. "Gates ... Foundation Funds Major New Collaboration to Accelerate HIV Vaccine Development - DukeHealth.org". dukehealth.org. 19 July 2006 ...

*South African AIDS Vaccine Initiative

The South African AIDS Vaccine Initiative or SAAVI is a South African organisation with the mission of coordinating the ... Faul, Michelle (20 June 2009). "South Africa launches AIDS vaccine trial but slashes research funding". washingtonexaminer.com ... SAAVI announced that it was testing a new HIV vaccine candidate but suspended all further vaccine development indefinitely due ... SAAVI frequently partners with the HIV Vaccine Trials Network.[citation needed] In June 2009, ...

*Mucosal immunology

Bourinbaiar, Aldar S.; Metadilogkul, Orapun; Jirathitikal, Vichai (2003). "Mucosal AIDS Vaccines". Viral Immunology. 16 (4): ... the mucosal immune system is being investigated for use in vaccines for various afflictions, including AIDS and allergies. " ... "Recent progress in HIV vaccines inducing mucosal immune responses". AIDS (London, England). 28 (12): 1701-18. doi:10.1097/qad. ... Mucosal Immunity and Vaccines, August 2003 Pavot, V; Rochereau, N; Lawrence, P; Girard, MP; Genin, C; Verrier, B; Paul, S (31 ...

*Raghavan Varadarajan

Merck have tested the a few vaccines and some of the other proposals are being tested by International AIDS Vaccine Initiative ... and International AIDS Vaccine Initiative for the development of HIV vaccines. He has also mentored a number of scholars in ... International AIDS Vaccine Initiative. May 2, 2007. Retrieved October 19, 2016. "Seminar by Prof. Raghavan Varadarajan". ... his team developed a number of immunogens which have been demonstrated to have positive effect as HIV-1 vaccines and he holds ...

*Long-term nonprogressor

International AIDS Vaccine Initiative. [1] accessed Dec 2007. Archived October 9, 2006, at the Wayback Machine. Poropatich, ... AIDS. 20 (5): 685-9. doi:10.1097/01.aids.0000216368.23325.bc. PMID 16514298. Thorven M, Grahn A, Hedlund KO, Johansson H, ... "Mitochondrial DNA haplogroups influence AIDS progression". AIDS. 22 (18): 2429-2439. doi:10.1097/QAD.0b013e32831940bb. ISSN ... Without the symptoms of AIDS, many LTNP patients may not know they are infected. Genetic traits that confer greater resistance ...

*Remune

The International AIDS Vaccine Research (IAVA) issued a report on "Whole Killed AIDS Vaccines" in 1999 reviewing a diverse ... IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism ... doi:10.1046/j.1468-1293.2001.00051.x. IAVI Report on Whole Killed AIDS Vaccines. ... The vaccine, however, does not contain gp120 surface antigen as it falls off on fixation of HIV-1. As a result, only gp41 is ...

*SAV001

The International AIDS Vaccine Research (IAVA) issued a report on "Whole Killed AIDS Vaccines" in 1999 reviewing a diverse ... Immune Response BioPharma, Inc A Killed-Virus Vaccine for HIV/AIDS IAVI Report on Whole Killed AIDS Vaccines Welcome to the ... Whole Killed AIDS Vaccines US Patent: HIV COMBINATION VACCINE AND PRIME BOOST Sumagen Canada Homepage Curocom Homepage Schulich ... The SAV001-H vaccine is considered as the first genetically modified version of the killed whole HIV-1 vaccine. According to Dr ...

*Ian Gust

... particularly in the prevention of hepatitus and AIDS. Gust, Ian D.; Kahn, Patricia; Koff, Wayne C. (2007). AIDS Vaccine ... Gust's area of work is in the development of drugs and vaccines against viral diseases and he is best known for the development ... The most cited are: Gust, I.D. "Epidemiological patterns of hepatitis A in different parts of the world" (1992) Vaccine, 10 ( ... "Professor Ian Gust". Vaccine and Immunotherapy Technologies. Sir Mark Oliphant Conferences. 2008. Retrieved 11 April 2012. " ...

*Becton Dickinson

"International AIDS Vaccine Initiative Press Release". Archived from the original on 2011-07-16. "Foundation for Innovative New ... International AIDS Vaccine Initiative, Foundation for Innovative New Diagnostics, Juvenile Diabetes Research Foundation, ... 1 million contribution to the International AIDS Vaccine Initiative (2002.) In 2003 and 2004, BD introduced several innovative ... This innovative product was used in a large-scale field test of the polio vaccine developed by Dr. Jonas Salk. One year later, ...

*Medroxyprogesterone acetate

AVAC (January 27, 2015). "News from the HC-HIV front: it's raining meta (analyses)!". New York: AIDS Vaccine Advocacy Coalition ...

*Hildegund C.J. Ertl

"Building a better vaccine Hildegund Ertl and her Philadelphia researchers pursue a new way to conquer the AIDS virus, threats ... human papilloma virus vaccines, rabies vaccine models, universal influenza vaccine, vaccines to Epstein-Barr virus, and using ... Her research is focused on developing vaccines for AIDS and various forms of cancer. Her lab is currently working on projects ... In interviews, Ertl has been cautious and critical when it comes to the development of vaccines for AIDS. Her research has ...

*Zinc finger nuclease

AIDS vaccine- Washington, Seattle 2007, :P05-01. Wayengera, M (2007). "A Recombinant lactobacillus strain producing restriction ... It is also hoped that, when applied to non-HIV infected persons, this strategy could offer a genomic vaccine against HIV and ... Stone, D.; Kiem, H. P.; Jerome, K. R. (2013). "Targeted gene disruption to cure HIV". Curr Opin HIV AIDS. 8. Coakley, E.; ... Alkhatib, G (2009). "The biology of CCR5 and CXCR4". Current Opinion in HIV and AIDS. 4 (2): 96-103. doi:10.1097/coh. ...

*Correlates of immunity/correlates of protection

International AIDS Vaccine Initiative HIV Vaccine Trials Network. ... The fact that the correlates of immunity/protection remain unclear is a significant barrier to HIV vaccine research. There is ... However, without knowing the correlates of immunity, scientists cannot know exactly what sort of immune response a vaccine ... suggesting that immunity and therefore a vaccine is possible. ... and the only method of assessing vaccine effectiveness will be ...

*Scripps Research Institute

"Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery". scripps.edu. "Scripps Center for Metabolomics and Mass ... The institute also incorporates the: Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery Center for Integrative ...

*Alan Bernstein

Newspaper Article". IAVI report : newsletter on international AIDS vaccine research. 12 (6): 18-21. PMID 20218020. Chabot, B.; ... Global HIV Vaccine Enterprise. VaccineEnterprise.org. McLaughlin Medal. Royal Society of Canada. Genetics Society of Canada ... Prior to his position at CIFAR, Bernstein was the inaugural executive director of the Global HIV Vaccine Enterprise, an ... Gewin, V. (2007). "Alan Bernstein, executive director, Global HIV Vaccine Enterprise, Seattle, Washington". Nature. 450 (7167 ...

*United States Military HIV Research Program

dead link] McNeil Jr, Donald G. (2009-09-25). "For First Time, AIDS Vaccine Shows Some Success". New York Times. Retrieved 2009 ... MHRP scientists are also pursuing other global vaccine strategies, which include MVA vaccines developed by MHRP and NIAID ... In addition to vaccine development and testing, MHRP also conducts therapeutic research, tracks the HIV epidemic in active-duty ... MHRP is distinct from the Defense HIV/AIDS Prevention Program, which was instituted in the late 1990s to address the spread of ...

*Mary Lou Clements-Mann

An Expert on AIDS Vaccines". The New York Times. Retrieved July 18, 2014. ... Mary Lou Clements-Mann was the longtime head of the Division of Vaccine Sciences at the Johns Hopkins Bloomberg School of ... She was a member of the US Centers for Disease Control Advisory Committee on the Children's Vaccine Initiative and the World ... Public Health, and is well known for her knowledge and work in HIV and AIDS. She died in the 1998 crash of Swissair Flight 111 ...

*Cervical cancer

The vaccines are between 92% and 100% effective against HPV 16 and 18 up to at least 8 years. HPV vaccines are typically given ... Also, not only does it aid in the development of HPV, but also if the woman is already HPV-positive, she is at an even greater ... The vaccines have been shown to be effective for at least four to six years, and they are believed to be effective for longer; ... HPV vaccines protect against between two and seven high-risk strains of this family of viruses and may prevent up to 90% of ...

*CureVac

In September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the ... Vaccine Prize". "CureVac, Sanofi Paster in 150m-euro-plus vaccines deal". "Boehringer pairs its lung cancer drug with a vaccine ... "IAVI and CureVac partner to further AIDS vaccine candidates". "CureVac Opens up an mRNA Hub in Moderna's Cambridge Backyard , ... Melinda Gates Foundation and the International AIDS Vaccine Initiative. CureVac's technology platform was developed in the late ...
Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine ...
INACTIVATION: HIV VACCINE RESEARCH AND DESIGN - R01 GRANTS Release Date: October 4, 1999 PA NUMBER: PA-98-089 National Institute of Allergy and Infectious Diseases The National Institute of Allergy and Infectious Diseases (NIAID) is inactivating program announcement PA 98-089, HIV VACCINE RESEARCH AND DESIGN - RESEARCH PROJECT GRANTS, which appeared in the NIH Guide, July 9, 1998. The areas of investigator-initiated vaccine research this PA targeted have received numerous responses that have been well-received in the NIH peer review system. Accordingly NIAID will no longer give special consideration for funding to applications in response to this PA received after January 2, 2000. NIAID will, however, continue to give special consideration for funding to applications in response to PAR 98-090, HIV VACCINE RESEARCH AND DESIGN - PROGRAM PROJECT GRANTS, which also appeared in the NIH Guide, July 9, 1998. NIAID supports highly scientifically meritorious applications in all areas of research within ...
Prospective cohort study of the clinical course of HIV-1 infection occurring after candidate HIV-1 vaccination (breakthrough infection) with ALVAC-HIV (vcP1521) and AIDSVAX B/E. This study will enroll volunteers who become HIV-infected during the course of follow up in a phase III preventive HIV vaccine trial conducted in Rayong and Chon Buri, Thailand. Volunteers will be enrolled in this protocol to provide additional long-term follow up to establish whether differences in viral load after infection (comparing vaccine to placebo) are associated with altered disease outcomes, as well as provide more detailed immunologic and virologic assessment of these volunteers ...
AIDS Cooperative Adjuvant Groups conduct preclinical studies of adjuvants and vaccine-adjuvant combinations.. AIDS Vaccine Reagent Project provides large quantities of reagents for preclinical and clinical studies related to vaccines.. Antibody Serologic Project identifies and standardizes monoclonal antibodies to characterize specific components of HIV and SIV.. AVEG (AIDS Vaccine Evaluation Group) includes six centers conducting Phase I and II trials of potential HIV vaccines.. AVEU (AIDS Vaccine Evaluation Unit) is an individual clinical site in the AVEG.. Chimpanzee Unit is a site for the evaluation of HIV vaccine concepts and products in chimpanzees.. Cooperative Mucosal Immunology Group for Investigations on AIDS Vaccines examines ways to stimulate and evaluate mucosal immune responses to HIV and SIV infection and vaccines.. DSMB (Data and Safety Monitoring Board) is an independent committee associated with the AVEG that reviews data of trials in progress to ensure that no participant is ...
EPALINGES, Switzerland, Jan. 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the companys first preventative HIV vaccine has been well tolerated.
GlobalData, the industry analysis specialist, has released its new report, "Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.. ...
An HIV/AIDS vaccine candidate developed by researchers at Oregon Health & Science University appears to have the ability to completely clear an AIDS-causing virus from the body.
Jamie Scott, a Simon Fraser University professor and Canada Research Chair in molecular immunity, and three international collaborators are getting a hefty financial boost in their efforts to develop an effective HIV/AIDS vaccine.. The United States National Institutes of Health (NIH) has awarded the four researchers $2.7 million to help them improve the effectiveness of a DNA-based vaccine that Marinieve Montero first conceived of eight years ago. Montero was a student of Scotts whose work was also funded by the NIH, the U.S.s largest government-funded medical research agency.. Scotts current collaborators are at the University of the Basque Country, the University of Massachusetts School of Medicine and the University of California, San Francisco.. The researchers will use their new funding to strengthen a vaccine theyve made from a DNA fragment taken from the HIV genome. The fragment encodes something that is highly prized in HIV/AIDS vaccine research. Called the MPER, its a region of ...
Important unanswered questions remain in the development of an effective AIDS vaccine, which could be a decade or more away, a top AIDS Researcher said ...
The massive growth in global health research in past decades has posed many challenges for its effective ethical oversight, not least of which is how best to provide effective protection of research participants. The extent of the HIV epidemic in sub-Saharan Africa in particular makes research into prevention technologies for HIV, including HIV vaccine research, a global priority. However, the need for vaccine research must be considered in conjunction with the individuals right to informed consent, which is based on the principle of respect for autonomy. One of the primary human rights violations likely to occur in the context of HIV vaccine research is that potential research participants may not fully understand what participation in research studies entails. People who elect to enrol in HIV vaccine trials are required to understand both the potential negative effects of participation (eg, discrimination) as well as complex scientific concepts such as randomisation and prophylaxis in order ...
Experimental HIV/AIDS vaccines under development by Merck and Sanofi-Aventis are entering crucial stages, and results from clinical trials for both ...
Background With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research into HIV vaccines and drugs. Sub-Saharan African countries - worst affected by the HIV pandemic - have participated in the conduct of clinical trials for HIV vaccines. In Kenya, the Kenya AIDS Vaccine Initiative (KAVI) at the University of Nairobi has conducted HIV vaccine clinical trials since 2001. Methodology Participants were recruited after an extensive informed consent process followed by screening to determine eligibility. Screening included an assessment of risk behavior, medical history and physical examination, and if clinically healthy, laboratory testing. In the absence of locally derived laboratory reference ranges, the ranges used in these trials were derived from populations in the West. Principal findings Two hundred eighty-one participants were screened between 2003 and 2006 for two clinical trials. Of these, 167 (59.4%) met the inclusion/exclusion criteria. Overall,
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
To augment the immune responses elicited by these and other vaccines, scientists use immunologic adjuvants. Currently, only one adjuvant -- alum, first discovered in 1926 -- is incorporated into vaccines licensed for human use by the U.S. Food and Drug Administration (FDA). An adjuvant may work well with one experimental vaccine and not another. Therefore, the FDA licenses the vaccine formulation, or the antigen-adjuvant combination, rather than the adjuvant alone. Experimental adjuvants can increase the type, strength and durability of immune responses evoked by an experimental vaccine. For example, some vaccine antigen/adjuvant combinations can induce cell-mediated immune responses, even if the vaccine antigen by itself does not. Some adjuvants also stimulate mucosal immunity. Alum primarily increases the strength of antibody responses generated by the vaccine antigen. Because of its limited activity, other adjuvants may be better suited for the newer candidate HIV vaccines ...
EPALINGES, SWITZERLAND--(Marketwired - April 11, 2016) - Mymetics Corporation (OTCQB:MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys...
Designing an effective HIV/AIDS vaccine is something of a paradox: a good vaccine would be safe and look enough like HIV to kick-start the immune system into neutralizing the virus - but the problem is that this is exactly what the human immune system has trouble doing even when its exposed to the real thing.. Now a team of researchers led by scientists at The Scripps Research Institute in La Jolla, CA has developed a strategy for inducing a key part of an effective immune response to HIV. By tracing the evolution of HIV-recognizing molecules called antibodies taken from the blood of rare individuals whose immune systems are naturally able to target and neutralize the virus, they may have found a way to replicate this for everybody.. At a talk next week at the American Crystallographic Association meeting in Hawaii, the team will present multiple crystal structures, which like detailed architectural blueprints show how the virus interacts with components of the immune system. Examining these ...
Additional research on public and private demand for HIV vaccines is needed to strengthen ongoing advocacy and planning for eventual vaccine introduction, say Hecht and Suraratdecha.
The breakthrough manufacturing technology developed by Vivalis, and now to be further developed through collaboration with GeoVax, will create a new standard for manufacture of the MVA component of the GeoVax HIV/AIDS vaccine, making present manufacturing technologies which have limited production capabilities, less competitive. Vivalis EBx® manufacturing platform, with its increased effectiveness, superior quality and reliability, will speed time to market MVA vaccine product availability in ample quantities to meet sizeable demand and expectedly at a lesser cost ...
A vaccine efficacy trial (known as HVTN 702) in South Africa (started 2016),. The AMP study in the Americas, Europe and Africa (started 2016), and. A vaccine trial (known as HPX2008/HVTN 705) in several African countries (expected to start in 2017/2018). HVTN 702 is testing a vaccine adapted from the one in RV144, while AMP, which stands for Antibody Mediated Prevention, is testing a different approach known as passive immunization. In the AMP study, participants will receive anti-HIV antibodies directly through an intravenous infusion, commonly known as an "IV" or "getting a drip". The findings of the AMP study will advance the HIV vaccine field.. Zimbabwe is part of the global partnership dedicated to HIV vaccine research, and is part of the AMP study.. The University of Zimbabwe-University of California San Francisco Collaborative Research Programme (UZ-UCSF)s Seke South Clinical Research Site (CRS) was selected as a protocol-specific site by the US National Institutes of Healths HIV ...
Sanofi Pasteur announced the results of a Phase 3 trial with its HIV prime vaccine, ALVAC HIV (recombinant canarypox vCP1521) in combination with the booster AidsVax B/E (recombinant gp120 vaccine, from VaxGen).
Researchers hope that this oral vaccine will create a more robust immune response against HIV. "We think that an oral approach may be the way to create a more effective vaccine and Im sure that most people would rather get a vaccine in a pill rather than by yet another shot," said Michael C. Keefer, M.D., professor of Medicine and director of the Universitys NIH-supported HIV Vaccine Trials Unit. John J. Treanor, M.D., professor of Medicine and chief of Infectious Diseases at UR Medicines Strong Memorial Hospital is leading the study with support from Keefer, who has more than 20 years of experience in the preventive HIV vaccine field. They will monitor how peoples immune systems respond to the vaccine and if the vaccine causes any symptoms. The University has a long track record of conducting detailed studies of HIV vaccines, but Keefer says that this is the first time an oral vaccine has been tested in Rochester. Though the research is in its early stages, he believes the information ...
Experts at a four-day global HIV/AIDS vaccine conference in Cape Town, South Africa, that opened Monday plan to seek fresh strategies against the ...
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Center for HIV/AIDS Vaccine Immunology (CHAVI) RFA-AI-04-051. NIAID
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).
What can you do to maintain your health at age 65 or older? More than you might think! This article will focus on one aspect of health maintenance: preventive vaccines. Flu vaccine During flu epidemics, the hospitalization rate for older people increases two to five times.
TY - CHAP. T1 - Challenges in designing HIV env immunogens for developing a vaccine. AU - Srivastava, Indresh K.. AU - Holland Cheng, R.. PY - 2008/1/1. Y1 - 2008/1/1. N2 - HIV continues to be a major health problem worldwide; however, the situation is particularly serious in Asian and Sub-Saharan countries. Development of an effective HIV vaccine could help to reduce the severity of the disease and prevent infection. Over the last two decades significant efforts have been made toward inducing potent humoral and cellular immune responses by vaccination; however, it appears that either antibodies or CTL may not be sufficient alone for the induction of sterilizing immunity or long-term control of viral replication. Therefore, it is generally believed that both humoral and cellular responses will be needed for an effective HIV vaccine. It has been shown in passive transfer experiments using broadly neutralizing monoclonal antibodies (mAb) such as b12, 2F5, and 2G12 that these mAbs either alone or ...
According to the report Middle East and Africa Preventive Vaccines Market, published by Market Data Forecast, the market is projected to reach USD 4.28 bil
Global Preventive Vaccines Market - offers growth, outlook, trends, shares, Industry Analysis, opportunities, Key Players Forecast 2018 to 2024
Recently, the Merck pharmaceutical company reported that its experimental HIV vaccine raised the rate of HIV infection among people who got the trial vaccine. Yes, you read that right. It was worse than nothing. This vaccine was composed of a few HIV proteins strapped onto an adenovirus, which causes colds. Among people with good immunity to this common cold virus, about 80% of the population, it increased the chances of contracting HIV. The saddest part is that this is not surprising. Virologists have long been skeptical about the possibility of an effective HIV vaccine. HIV infects the very immune cells that you stimulate to defend your body against it. Stimulating these cells increases the rate at which HIV can infect those cells and the rate of HIV replication in these cells. Thus, an HIV vaccine can make it more likely that you’ll get AIDS, and you might get it sooner and worse than if you weren’t immunized. So far, no one has found the Holy Grail of HIV vaccines: a ...
BACKGROUND RV144 is the only preventive HIV vaccine regimen demonstrating efficacy in humans. Attempting to build upon RV144 immune responses, we conducted a phase 1, multicenter, randomized, double-blind trial to assess the safety and immunogenicity of regimens substituting the DNA-HIV-PT123 (DNA) vaccine for ALVAC-HIV in different sequences or combinations with AIDSVAX B/E (protein).METHODS One hundred and four HIV-uninfected participants were randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0, 1, 3, and 6 months (M): T1 received protein at M0 and M1 and DNA at M3 and M6; T2 received DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadministered at M3 and M6; and T4 received protein and DNA coadministered at each vaccination visit.RESULTS All regimens were well tolerated. Antibodies binding to gp120 and V1V2 scaffold were observed in 95%-100% of participants in T3 and T4, two weeks after final ...
Any future HIV (human immunodeficiency virus) vaccine will rely on inducing either antibodies that neutralize the virus, or cell-mediated immunity by cytotoxic T lymphocytes (CTLs). The former initiative is being frustrated by the ability of the virus to mutate and escape antibody binding. Although a related problem of viral escape is faced by CTLs, it does appear that a robust cell-mediated immune response can lower the levels of replicating virus after acute infection, and this set-point is known to affect the course of subsequent infection and progression to AIDS. Using infection of monkeys with the pathogenic SIV, the simian cousin of HIV, Letvin et al. (p. 1530) offer direct experimental evidence that generation of a robust cellular response by vaccination corresponds with increased survival. This finding also correlated with the persistence of high numbers of so-called central memory T cells and suggests that finding ways of preserving these important lymphocytes may help in improving ...
The STEP study, also known as the HVTN 502 or Merck V520-023 study, is a clinical trial to continue evaluating the safety and begin evaluating the ...
Nearly 37 million people are living with HIV around the world. In the United States, 1.2 million people are living with HIV, of whom 13 percent are unaware of their diagnosis. Although progress has been made in the global fight against HIV/AIDS, the epidemic continues in the United States and the international community. Globally, AIDS-related deaths have dropped by 45 percent since their peak in 2004. Yet the rate of HIV transmission remains unacceptably high, with 2.1 million new infections occurring worldwide in 2015 alone. Source: NIH-NIAID. ...
An HIV vaccine is a vaccine which would either protect individuals who do not have HIV from contracting that virus, or otherwise may have a therapeutic effect for persons who have or later contract HIV/AIDS. Currently, there is no effective HIV vaccine but many research projects managing clinical trials seek to create one. There is evidence that a vaccine may be possible. Preventative medications such as antiretroviral treatments have been put into use to help prevent infection, but do not work as well as a vaccine would. Work with monoclonal antibodies (MAb) has shown or proven that the human body can defend itself against HIV, and certain individuals remain asymptomatic for decades after HIV infection. Potential candidates for antibodies and early stage results from clinical trials have been announced. One HIV vaccine candidate which showed some efficacy was studied in RV 144, which was a trial in Thailand beginning in 2003 and first reporting a positive result in 2009. Many trials have shown ...
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
A new study gives a much-needed booster shot to the beleaguered AIDS vaccine field. The experiment, led by immunologist and pathologist Louis Picker of the Oregon Health & Science University in Beaverton, showed that an unusual approach to vaccinating against SIV (a simian cousin of HIV) protected 12 of 24 monkeys from a "challenge" with a particularly virulent strain of that virus. Specifically, all monkeys became infected, but in half of the animals, their immune systems drove the virus down to undetectable levels for more than a year. "Its the best result Ive seen against the worst SIV known," says the University of Wisconsins David Watkins, an immunologist who tests AIDS vaccines in monkeys and was not involved with the work. "Im very excited by this approach.". The vaccine contains SIV genes stitched into cytomegalovirus (CMV), a herpesvirus that harmlessly infects many humans and serves as the delivery vehicle, or vector, for the AIDS virus proteins. Typically, AIDS vaccines use ...
A large-scale phase IIb clinical trial of a candidate HIV vaccine has begun in South Africa. This vaccine has shown promise in smaller U.S. studies. The trial involves 3,000 HIV-negative men and women, making it the largest African HIV vaccine trial to date. The study vaccine is provided by Merck & Co., Inc. and contains copies of only three HIV genes, not the entire virus, so it is impossible for trial volunteers to become infected from the vaccine. The South African trial is called Phambili (HVTN 503), which literally means "moving forward." It is designed to provide preliminary information on vaccine efficacy and thus enable researchers to decide whether or not to conduct a larger phase III efficacy trial that could lead to licensure. In smaller trials, the vaccine was found to be safe and to stimulate cellular immune responses against HIV in more than half of the volunteers. The primary objectives of HVTN 503 are to determine whether the candidate vaccine can prevent HIV infection or, in ...
The US government is poised to start a new AIDS vaccine trial, prompting some to caution that it is too soon to initiate such studies after a linkurl:Merck vaccine;http://www.the-scientist.com/blog/display/53633/ not only failed to show effectiveness but also may have increased participants HIV infection rate. Late last week, the NIHs linkurl:AIDS Vaccine Research Subcommittee;http://www3.niaid.nih.gov/research/topics/HIV/vaccines/advisory/avrs/ voted 23-3 in favor of beginning the PAVE 100 H
NIAID-supported investigators are conducting an abundance of research on all areas of HIV infection, including developing and testing preventive HIV vaccines, prevention strategies, and new treatments for HIV infection and AIDS-associated opportunistic infections. Through laboratories and clinics on the National Institutes of Health campus in Bethesda, Maryland, and a vast network of supported research at universities, medical centers, and clinical trial sites around the globe, NIAID is working to better understand HIV and how it causes disease, find new tools to prevent HIV infection including a preventive vaccine, develop new and more effective treatments for people living with HIV, and hopefully, find a cure.. ...
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
Long before Buffetts offer was revealed, the Gates foundation made known its interest in funding vaccine research. It has contributed $126.5 million to the International AIDS Vaccine Initiative, a private, nonprofit financier of vaccine research and development based in New York. "One thing about the Gates foundation is that they are prepared to be there in the long run. An AIDS vaccine is not something to be solved overnight," said Dr. Robert Hecht, the Vaccine Initiatives senior vice president for public policy. ...
Chinese-developed AIDS vaccine has won government approval to be tested by human bodies, Xinhua reported Friday quoting sources with the State Food and Drug Administration (SFDA) of China. The news agency said, the compound vaccine consists of DNA vaccine and regrouped virus carrier. Chinese scientists began the research by studying domestically popular virus genes in 1996, including the envelope albumen and core albumen of the virus. They found that human body will become immune to AIDS virus after injecting DNA vaccine and regrouped virus carrier in succession. Researchers attacked a monkey with AIDS virus after injecting the compound vaccine into its body, and found no abnormal reactions occurred. Human body test, or stage I clinical test, of the compound AIDS vaccine aims to further assess the security of the vaccine, an SFDA official said. The government will consider whether to launch stage II and stage III tests on the basis of the result of the stage I test. SFDA officials said that they ...
Health,...TORONTO ON On the eve of the worlds biggest AIDS conference this mo...The authoritative review published in this months edition of the jou... One might assume that if an HIV vaccine was available many people wo...Newman and Logies meta-analysis of existing literature identified sev...,Future,HIV,vaccines:,If,we,build,it,,will,they,come?,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Then the Thai government did an amazing thing: it acknowledged the importance of HIV, identified the source and instituted a prevention program, enforcing condom use in brothels. The impact was dramatic. Rates of infection declined precipitously and prevalence in sentinel populations fell. The epidemic was changing before a vaccine could be brought to the field. As incidence dropped, the trial had to become larger and compromises had to be introduced.. Initial plans called for optimizing both cellular and humoral HIV-specific responses using a "prime-boost" approach: a single prime (ALVAC-HIV, a CRF01-specific canarypox vaccine) was to be tested with three different boosts (subunit vaccines) in phase II trials from which the best regimen would be chosen for the Phase III trial. Shortly before the Phase II trials were complete, two of the manufacturers withdrew their products. The ALVAC-HIV + AIDSVAX B/E combination, the only regimen remaining, "passed" immunogenicity criteria for advancement to ...
Researchers report a breakthrough in generating powerful antibodies that can neutralize HIV. An HIV infection is really an intensive molecular arms race launched from the minute the virus infects a new host. AIDS progresses not because the body isnt capable of fighting off HIV - it is.
IDM Pharma, Inc. today presented preliminary results from a Phase II UVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202).
Merck has been testing a candidate HIV vaccine in two large phase II clinical trials; the STEP study in North and South America, the Caribbean and Australia, and a parallel study called Phambili in South Africa. STEP was a multi-center, randomized, double-blind, placebo-controlled phase II test-of-concept clinical trial. Started in December 2004, enrollment in the study was completed by March 2007 and more than 2,500 participants had received all three doses of vaccine or placebo. STEP was evaluating two primary efficacy endpoints ...
A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa and South America.
AIDS vaccine Worse Than Useless?_ISS. Wed, 25 Jun 2003 An article published by the Institute of Science and Society (ISS locatedin the UK) cautions that experience thus far with 51 NIH-sponsored AIDSvaccinetrials (Phase I and II) belie the claimed positive findings made in anarticle in the currentissue of Vaccine, which concluded that there were no adverse effects in 3189HIVuninfected, healthy volunteers who were enrolled.. But Dr. Mae-Wan Ho the author of the ISS article (excerpt below) notes:"The only AIDS vaccine to have progressed past phase 3 trial, made byVaxGen,took 5 years and involved 5108 gay men and 309 women. Unfortunately, itprovedineffective, and may even be harmful.". "In the 3003 white and Hispanic volunteers who received VaxGens vaccine,a higher proportion suffered breakthrough infections than in the 1508controls:6% vs 5%. Although the difference is not significant, it could indicate adangerous trend. But the company is not releasing further details on thetrialresults.". Dr. ...
The Annual Meeting has a traditional emphasis on the biology of HIV/AIDS, including the perspectives of basic science, clinical science and new treatment and prevention approaches. In 2010 we are expanding the emphasis on vaccines to recognize the importance of this area and learn how recent successes may guide new directions in HIV vaccine research and development. International vaccine experts will describe vaccine immunogens that are moving through human clinical trials, efforts to define immune correlates of protection, possible applications for therapeutic vaccination and a range of vaccine delivery strategies that are bringing us closer, everyday, to effective protection from HIV disease. Recognizing the important parallels of HIV and cancer, we include discussions of cancer-causing viruses, new cancer vaccines and fundamental research in cancer. In developed countries, cancer is emerging as the leading cause of death for persons with HIV, and these fields are inexorably linked in terms of ...
Does the dramatic decrease in new Zika virus cases during 2017 indicate that the threat has passed? Has the need for a preventive vaccine diminished? Neither is true. When the Zika virus reactivates, not having a commercially available vaccine will be unfortunate. In recent years, the Zika virus has had a devastating impact across more than 84 countries, territories and subnational areas, including the U.S. Recently, two international pharmaceutical manufacturers announced some good and bad news.
The stock of Sheffield Medical Technologies Inc., a medical development company based in Houston, rose yesterday on news that the company had acquired a worldwide license to an H.I.V.-AIDS vaccine technology under development. Shares of Sheffield rose $1.1875, to $5.75. The company said late on Tuesday that it had the sole option to obtain an exclusive worldwide license to an H.I.V.-AIDS vaccine being developed by Prof. Jean-Claude Chermann at the French National Institute of Health and Medical Research in Marseilles, France. Prof. Chermann said he had developed an antibody that in laboratory tests on apes appeared to prevent the H.I.V. virus from penetrating cells and reproducing. Vaccines work through the injection of viral proteins into the body to stimulate the immune system to produce antibodies that protect cells from invading viruses like H.I.V., which causes AIDS.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.
This animation, developed for the International AIDS Vaccine Initiative, demonstrates how an AIDS vaccine might work in the body. Created for IAVIs presentation at the 2010 TED conference, this video takes a look at key players in the immune system and shows the anticipated immune response to HIV after vaccination.. ...
a_phase_1_clinical_trial_to_test_a_novel_hivaids_vaccine_has_begun_at_brigham_and_womens_hospital_bwh_this_new_vaccine_aims_to_overcome_the_problem_of_preexisting_immunity_to_common_vaccine_vectors_which_is_thought_to_be_a_major_problem_in_the_developing_world_
After 2 years of analyzing the results of the largest AIDS vaccine clinical trial ever held - called RV144 - researchers say they have found 2 ways the immune system can respond, which could predict whether those inoculated will be protected or are more likely to become infected with HIV.
For the first time, an HIV vaccine trial has produced positive results: A new vaccine tested on more than 16,000 volunteers in Thailand reduces the risk of HIV infection by more than 30 percent, The New York Times reports.
The Merck candidate vaccine showed good HIV-specific immunogenicity in Phase I and II studies (see http://www.hvtn.org/science/1107.html for the recently released STEP trial results) as measured mostly by a single parameter: the IFN-γ ELISPOT assay. The rAd vaccine also induced long-lasting, multifunctional responses as monitored by polychromatic flow cytometry (http://www.hvtn.org/fgm/1107slides/McElrath.pdf). Indeed, after homologous prime-boost immunization with a replication-defective adenovirus-based vaccine, a majority of responders had HIV-specific CD8+ T lymphocytes that were capable of producing CD107, macrophage inflammatory protein 1β, IFN-γ, and TNF, and antigen-specific CD4+ T cells that were able to produce IFN-γ, interleukin (IL)-2, and TNF (Casimiro, D., personal communication). The CD8 T cell responses to HIV antigens, however, were not particularly broad. A median of three peptide pools, each consisting of overlapping 9-amino acid peptides spanning a 16-amino acid region of ...
The Merck candidate vaccine showed good HIV-specific immunogenicity in Phase I and II studies (see http://www.hvtn.org/science/1107.html for the recently released STEP trial results) as measured mostly by a single parameter: the IFN-γ ELISPOT assay. The rAd vaccine also induced long-lasting, multifunctional responses as monitored by polychromatic flow cytometry (http://www.hvtn.org/fgm/1107slides/McElrath.pdf). Indeed, after homologous prime-boost immunization with a replication-defective adenovirus-based vaccine, a majority of responders had HIV-specific CD8+ T lymphocytes that were capable of producing CD107, macrophage inflammatory protein 1β, IFN-γ, and TNF, and antigen-specific CD4+ T cells that were able to produce IFN-γ, interleukin (IL)-2, and TNF (Casimiro, D., personal communication). The CD8 T cell responses to HIV antigens, however, were not particularly broad. A median of three peptide pools, each consisting of overlapping 9-amino acid peptides spanning a 16-amino acid region of ...
Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the viruss extensive genetic diversity.
Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the viruss extensive genetic diversity.
Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according
...An AIDS vaccine tested in people but found to be ineffective influen...The results were published Feb. 27 in Nature Medicine . ...This is the first evidence that vaccine-induced cellular immune respon...The senior author of the multi-institutional study is Dr. James I. Mul...,For,first,time,,scientists,show,an,HIV,vaccine,impacts,the,genetic,makeup,of,the,virus,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
A radical new type of vaccine has shown positive results during tests on HIV-positive patients, bolstering hopes of fully protecting humans from AIDS in the future, researchers say.. A new type of molecule, used in the vaccine, was engineered by scientists at the Scripps Research Institute in California, which they claim blocks the HIV virus from attaching to cells, the Independent reported on Wednesday.. Usually HIV vaccination works by provoking a response in the immune system, but the new vaccine has a different approach.. During experiments initially reported in the journal Nature, the researchers discovered that four monkeys injected with the vaccine, which works by altering DNA, were protected for at least 34 weeks from all types of HIV.. Even though the new vaccine still requires human testing, experts have said it represents an "exciting" development in the fight against AIDS.. "We are closer than any other approach to universal protection, but we still have hurdles, primarily with ...
AIDS (Acquired Immune Deficiency Syndrome) was identified as a global pandemic and "a threat to world security" by the Clinton administration in July 2000. President George W. Bush has pledged $15 billion to combat AIDS, and additional hundreds of millions of dollars have been donated by rich countries and charitable foundations.. Yet every aspect of the disease has been subject to acrimonious debate. Is AIDS a real disease? Is it a single disease? What is the real extent of the AIDS pandemic? Does HIV cause AIDS? Is AIDS sexually transmitted? Do conventional anti-HIV drugs do more harm than good? Are the candidate anti-HIV vaccines effective, or even safe? Are there safe and effective treatments that can be made widely available at affordable costs? Big pharmaceutical companies profit from the sale of lucrative drugs and hope to profit even more from effective AIDS vaccines, which are still in the pipelines after more than two decades. AIDS is perhaps the most-researched yet most-misunderstood ...
Recently, the first data from the companion Phambili trial have become available [10]. This trial was conducted in South Africa and used the MRK Ad5 gag/pol/nef vaccine to investigate whether it would demonstrate efficacy in a clade C region. The trial enrolled 801 participants before it was stopped. Of the 11 acquisitions reported to date, nine were among those seropositive to Ad5. HIV acquisition occurred in six who received the vaccine and three who received placebo; the two HIV infections in the Ad5 seronegatives at entry were split one and one in each group; 10 of the 11 HIV infections were in women. These very preliminary results from South Africa continue to provide evidence that preexisting immunity to the Ad5 vector was an independent risk factor in the increased role of HIV acquisition among vaccine recipients. The placebo in these clinical trials was a saline solution, thus limiting the ability to evaluate the impact of the empty Ad5 vector on HIV-1 acquisition. This increased risk ...
An HIV vaccine candidate successfully primed a mouse model to produce broadly neutralizing antibodies to repel the virus. Human trials could begin in about two years.
Detailed results of the now-famous Thai AIDS vaccine trial confirmed that the vaccine is modestly effective, but hinted that its effect may fade over time.
The search for an AIDS vaccine is showing renewed promise with a report that a vaccine test on monkeys has been effective. However, because other techniques have also been successful with monkeys but failures with people, researchers remain cautious.. ...
lright this is for any of you that have family or friends that think vaccines are safe ask the this... Would you take a HIV Vaccine?
Researchers from the Perelman School of Medicine at the University of Pennsylvania have figured out how to make a much-improved research tool that they hope will open the door to new and better HIV vaccine designs.
Some individuals infected with HIV have a gene variant that keeps the virus in check. Researchers hope the natural protection could point the way to an AIDS vaccine. Steve Mirsky reports.
Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful ...
sex and your kid (1) Alarming Finding About Painkillers (1) Transformers 3 (1) Tried And True Diabetes Drug Still The Best After 15 Years (1) 11 Things to Know About HIV Testing (1) 12 Reasons Youre Not Losing Weight (1) 17 Day Diet (1) 7 Major Advances Predicted for Health Medicine in 2011 (1) 7-Year-Old Evan Mosss Inspiring Fight Against Epilepsy (1) 8 Simple Ways to Reduce Your Risk of Dementia (1) A Cupcake a Day Keeps the Doctor Away- The Search for The Queen (1) A Guide to Using the Nicotine Patch (1) ADHD (1) Adult Acne: How to Treat and Control Breakouts (1) Adult ADD/ADHD and Substance Abuse (1) agonizing (1) AIDS Vaccine (1) Almost 15 Million Alzheimers And Dementia Caregivers In USA Today (1) Alzheimers (1) Alzheimers Early detection (1) American Doctors (8) AMERICAN DOCTORS OBSERVES MEMORIAL DAY (1) Are baby boomers healthier than previous generations (1) Avoid frequent leg cramping (1) Bed sharing with a toddler (1) betrayal and a calling (1) Business Travel Linked to ...
Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, and the HIV Vaccine Trials
Mr. Cohen discussed his book [Shots in the Dark: The Wayward Search for an AIDS Vaccine], published by W.W. Norton. In his book and talk, Mr.
EHVA - EUROPEAN HIV VACCINE ALLIANCE, AN EU PLATFORM FOR THE DISCOVERY AND EVALUATION OF NOVEL PROPHYLACTIC AND THERAPEUTIC VACCINE CANDIDATES. Project aims: To develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials.. Project leader: Institut national de la santé et de la recherche médicale (INSERM). Main partners: Involves 39 institutions including Universities, Research Institutes, SMEs and larger industries.. EATG participation: Involved in WP 9: Therapeutic Vaccine Trials; WP 11: Dissemination and Exploitation. EATG is community partner in this project ensuring community feedback to the scientific developments within the project.. Duration: January 2016 - January 2021. Main funding source/programme: EC Horizon 2020. Budget: 50,000 EUR. Website: http://www.ehv-a.eu/. EATG contact person(s): ...
Site content is not intended to be a statement of A.A. policy. Announcements of a general interest are presented solely as a service, not as an endorsement. ...
A team of scientists from the National Institute of Allergy and Infectious Diseases and Duke University recently conducted a study to explain why the HVTN 505 trials candidate vaccine did not protect subjects against HIV infections.
A HIV-1 DNA prime-recombinant Adenovirus Type 5 (rAd5) increase vaccine failed to guard against HIV-1 acquisition. is certainly towards the gp41 subunit from the envelope (Env) glycoprotein from the pathogen (1). This antibody response derives from polyreactive B cells that cross-react with Env and intestinal microbiota (IM) (2, 3). Nevertheless, it is unidentified if an identical gp41-reactive Ab response would take place in the placing of HIV-1 Env vaccination. A DNA leading, recombinant adenovirus serotype 5 (rAd5) increase vaccine that included HIV and genes, and a trivalent combination of clade A, B and C gp140 genes formulated with both gp120 and gp41 elements was examined in the HIV Vaccine Studies Network (HVTN) [stage Ib (HVTN 082), GW-786034 stage II (HVTN 204), stage IIb (HVTN 505) efficiency trial] and various other clinical studies [stage I/II (RV172), stage I (V001)] (4C7). This vaccine was the GW-786034 initial vaccine formulated with the ectodomain from the Env gp41 component, ...
Researchers from around the world have been working for more than two decades to create a preventative vaccine that will protect the worlds population against HIV infection.
The new study shows how the presence of long-lasting Ad5-specific antibodies-generated during natural infections with adenoviruses-may have altered the immune response to the HIV vaccine. In the presence of antibodies from Ad5-immune individuals, HIV infection spread through cell cultures three times faster than without them. The antibodies tethered the Ad5-HIV vaccine to receptors on the surface of specialized immune cells, called antigen-presenting cells (APCs), thus facilitating entry of the vaccine into the cell. Once inside, components of the vaccine then activated these cells, allowing the APCs in turn to activate T cells. Since HIV prefers to infect active T cells, the virus was thus provided with more cells to infect. Mercks vaccine may have made it to phase II trials because primates, used in the phase 1 trials, dont naturally come in contact with human adenoviruses, and therefore the potential problem went unrecognized. ...
Health Disclaimer! The information provided on this site should not be construed as personal medical advice or instruction. No action should be taken based solely on the contents of this site. Readers should consult appropriate health professionals on any matter relating to their health and well-being. The information and opinions provided here are believed to be accurate and sound, based on the best judgment available to the authors, but readers who fail to consult appropriate health authorities assume the risk of any injuries. The publisher is not responsible for errors or omissions.. ...
According to a recent study, observing the evolution of a particular type of antibody in an infected HIV-1 patient has provided insights that will enable vaccination strategies that mimic the actual antibody development within the body.
Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging results. The vaccines had in fact triggered an antibody response -- now known to be associated with protection in adults -- that was previously unrecognized in the infants studied in the 1990s.
EMBARGOED FOR RELEASE until 12 p.m. noon (ET) on Thursday, March 3, 2016 DURHAM, N.C. - One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates.
Most people know that when you are diagnosed with some STDs, you can get it cured with a vaccine. What about preventative vaccines?
This portal is dedicated to specific TB learning. All HIV/TB evaluations are included in the HIV/AIDS portal: http://evaluation.msf.org/hivaids
Background: Making changes to municipal social care and service has been found to be challenging to realise and highly multifaceted. The aim of this study was to describe how the professionals can identify needs for improvement and improve Food Distribution (FD) service for the home-living elderly people in Sweden.. Methods: This study is part of a larger project with an action research approach focusing on to municipal FD to older people living in their own home in Sweden. The professionals involved in FD invited the first author to assist them in this process. The study participants were comprised of the following groups: "The Identification focus group" that identified need for improvement of FD (n= 5); "The Action focus group" that planned and choose suitable action for improvement (n=5); "The First Evaluation group" (n=4) that evaluated the content of planned improvement and finally "The Second Evaluation group" (n=29) that evaluated the changes following improvement. The data was ...
Liberal Democrat MP Dr Evan Harris is to test an experimental vaccine for Aids. BBC News Online examines what the procedure will entail.
MHRPs molecular epidemiologists played a key role on a research team that analyzed the HIV-1 genome sequences from infected volunteers in the Step HIV vaccine trial. Findings indicate that that although ineffective at preventing infection, the vaccine impacted the genetic makeup of the virus that infected the volunteers. Results were published Feb. 27 in Nature Medicine.
Summary: Pharmexa, together with the HIV Vaccine Trials Network, opens a phase I study to test the safety of two HIV vaccines developed by Pharmexa-Epimmune., , , , H rsholm, January 27, 2006, Pharmexa-Ep...
A new study by the federal National Institute of Allergy and Infectious Diseases shows that many Americans think a preventive vaccine for HIV already exists and is being kept secret. NIAID surveys showed that 48% of African-American and 28% of Latino respondents believe that such a vaccine has been developed and is being kept from the public. Overall, about 20% of the 3,500 adults surveyed reported believing that a secret vaccine exists. Other widely reported misconceptions include a fear that HIV vaccines can cause HIV infection in clinical trial volunteers.. To help debunk such beliefs, NIAID is sponsoring the sixth annual HIV Vaccine Awareness Day on May 18. The goal of the event is to provide accurate information about HIV/AIDS and HIV vaccine research to the public. "HIV vaccine research is our best hope, along with other prevention and treatment efforts, to slow the spread of HIV," said NIAID director Anthony Fauci. "NIAID is committed to educating the public to help correct misconceptions ...
Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
1) Injectable influenza vaccines reduce morbidity and mortality in people over 65 years. (2) A new influenza vaccine, with an adjuvant (MF59 C.1) based on squalene, is now marketed in France for people over 65, and especially those with chronic conditions at risk of influenza complications. (3) The clinical evaluation dossier contains data from about twenty immunogenicity studies in more than 4000 elderly subjects. According to a meta-analysis of these studies, there is no firm evidence that the MF59 C.1 adjuvant vaccine is any better than other vaccines at inducing immunity in elderly people with chronic conditions. (4) A retrospective analysis of mortality among subjects enrolled in immunogenicity studies showed no significant difference between groups receiving the squalene adjuvant vaccine and groups receiving another influenza vaccine, either in the general population or in subsets of patients with relevant chronic conditions. (5) Local adverse effects (pain, rash, induration) and systemic ...
Data & statistics on Cancer Vaccines: Number2of trials conducted by each lead sponsor Number of trials conducted by each lead sponsor. (a) The number of cancer vaccine trials conducted by each lead sponsor is plotted as a bar graph by the name of the sponsor. Only the sponsors who have conducted more than 10 cancer vaccine trials are depicted here. The height of the bar and the number on top of each bar represent the total number of trials ..., HIV/AIDS vaccines, malaria vaccines, tuberculosis vaccines, anti-cancer vaccines, anti-addiction vaccines anti-fertility vaccines, therapeutic vaccines., Konno, R., et al., Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer, 2010. 20(3): p. 385-392. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec, 2009. 84(15): p. 118-131. Quadrivalent vaccine against human papillomavirus to prevent...
Seattle BioMed today announced that it has received a seven year Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that would elicit broadly neutralizing antibodies against HIV-1. Seattle BioMed will lead a consortium comprised of the Rockefeller University, the University of Washington, Seattle Childrens Hospital and the Fred Hutchinson Cancer Research Center. The investigators will receive $9.8 million over seven years to fund the initial phase of the project which will include the optimization and preclinical evaluation of two vaccine candidates. The second phase of the project will include the production of these vaccines according to current Good Manufacturing Practices (cGMP) and the evaluation of their safety and immunogenicity in a Phase I clinical trial. Read more here.. ...
DNA vaccines or proteins are capable of inducing specific immunity; however, the translation to the clinic has generally been problematic, primarily due to the reduced magnitude of immune response and poor pharmacokinetics. Herein we demonstrate a composite microsphere formulation, composed of mesoporous silica spheres (MPS) and poly(d,l-lactide-co-glycolide) (PLGA), enables the controlled delivery of a prime-boost vaccine via the encapsulation of plasmid DNA (pDNA) and protein in different compartments. Method with modified dual-concentric-feeding needles attached to a 40 kHz ultrasonic atomizer was studied. These needles focus the flow of two different solutions, which passed through the ultrasonic atomizer. The process synthesis parameters, which are important to the scale-up of composite microspheres, were also studied. These parameters include polymer concentration, feed flowrate, and volumetric ratio of polymer and pDNA-PEI/MPS-BSA. This fabrication technique produced composite ...
The charter will be accompanied by an action plan to help signatories put it into practice.. An estimated 20 million people with disabilities are currently affected by humanitarian crises. Often marginalized in their communities of origin, people with disabilities can also find it more difficult than people without disabilities to flee affected areas and to access humanitarian aid. Their rights and needs are often not taken into account. According to a survey, Disability In Humanitarian Context, conducted by Handicap International in the first half of 2015: three quarters of people with disabilities affected by a humanitarian crisis and who responded to the survey reported that they did not have adequate access to basic assistance such as water, shelter, food, or health care services. Half of respondents reported that they did not have access to specific care such as rehabilitation and assistive devices.. "We invite all NGOs, States and humanitarian funding bodies to sign the Charter on ...
Looking for online definition of simian-human immunodeficiency virus in the Medical Dictionary? simian-human immunodeficiency virus explanation free. What is simian-human immunodeficiency virus? Meaning of simian-human immunodeficiency virus medical term. What does simian-human immunodeficiency virus mean?
Therapeutic vaccines function by triggering a body immune response against a disease. The global therapeutic vaccines market was valued at USD 292 million in 2011. The introduction of therapeutic vaccines has opened up new avenues in the field of chronic disease treatment and prophylactic immunization. Provenge was the first U.S. FDA approved immunotherapy drug to treat prostate cancer in men in 2010, which has encouraged rigorous research and development initiatives by pharmaceutical companies to develop novel vaccines for untapped disease segments. As a result of these initiatives, many more therapeutic vaccines are currently in the pipeline such as breast cancer vaccine, lung cancer vaccine; Alzheimers vaccine, malaria vaccine, and diabetes vaccine are expected to be introduced in the market during the period from 2012 to 2018. ...

HIV/AIDS Vaccines | News | AIDSinfoHIV/AIDS Vaccines | News | AIDSinfo

The NIAID AIDS Vaccine Clinical Trials Network includes the following:. * The AIDS Vaccine Evaluation Units (AVEUs) [known ... The NIAID AIDS Vaccine Clinical Trials Network is the largest cooperative HIV vaccine clinical trials group in the United ... This fact sheet summarizes NIAIDs approach to developing an HIV/AIDS vaccine. It describes the challenges facing vaccine ... the efficacy of candidate HIV vaccines in U.S. populations.. * An international HIV/AIDS vaccine efficacy trials master ...
more infohttps://aidsinfo.nih.gov/news/70/hiv-aids-vaccines

Progress Finding An AIDS Vaccine - RedorbitProgress Finding An AIDS Vaccine - Redorbit

Progress Finding An AIDS Vaccine. The search for an AIDS vaccine is showing renewed promise with a report that a vaccine test ...
more infohttp://www.redorbit.com/video/progress_finding_an_aids_vaccine/

New AIDS Vaccine Shows Promise | Fox NewsNew AIDS Vaccine Shows Promise | Fox News

The first preliminary human testing of a highly anticipated new kind of AIDS vaccine offers tantalizing hints it may ultimately ... The study of Merck & Co.'s experimental vaccine is perhaps the most closely watched experiment in all of AIDS research. ... We are encouraged, said Emini, head of Merck's AIDS vaccine program. Obviously, the big question is how effective this ... It is a more traditional vaccine, made from the outer wrapper of the AIDS virus. Results are expected later this year. ...
more infohttps://www.foxnews.com/story/new-aids-vaccine-shows-promise

AIDS Vaccine May Present New Woes - latimesAIDS Vaccine May Present New Woes - latimes

Although AIDS (Acquired Immune Deficiency Syndrome) seems to have appeared full-blown early in this decade, it is not without ... a vaccine is the best bet in the medical rush to stop AIDS from spreading. Yet the possibility of a vaccine presents a new set ... These men are an appropriate group to undergo the first round of vaccine testings. If the vaccine proves successful in ... has surveyed 644 homosexual men about their willingness to participate in a test of an AIDS vaccine. Forty-three percent said ...
more infohttp://articles.latimes.com/1986-05-28/news/vw-8063_1_aids-vaccine

Chinese AIDS vaccine tested by human bodyChinese AIDS vaccine tested by human body

Human body test, or stage I clinical test, of the compound AIDS vaccine aims to further assess the security of the vaccine, an ... Chinese AIDS vaccine tested by human body. (Agencies). Updated: 2004-11-26 13:01 ... According to experts, AIDS vaccine is the only solution to stop the wildfire spread of the grievous infectious disease. ... Chinese-developed AIDS vaccine has won government approval to be tested by human bodies, Xinhua reported Friday quoting sources ...
more infohttp://www.chinadaily.com.cn/english/doc/2004-11/26/content_395161.htm

Robinson brings AIDS vaccine to clinical trialsRobinson brings AIDS vaccine to clinical trials

Emorys AIDS vaccine consists of two components: a DNA prime and a recombinant poxvirus as a booster. The vaccine is designed ... Center for manufacture of the vaccine. By late 2004, the Vaccine Center hopes to begin a Phase I trial of a trivalent vaccine ... Robinson projects that Phase III efficacy trials of the AIDS vaccine could begin in 2006. Unlike the much smaller Phase I and ... A California biotech company, ViCal, manufactured the priming components of the AIDS vaccine for the Phase I clinical trial ...
more infohttp://www.emory.edu/EMORY_REPORT/erarchive/2002/November/erNov.4/11_4_02robinson.html

Breakthrough raises hope for AIDS vaccine | The StarBreakthrough raises hope for AIDS vaccine | The Star

The long thwarted dream of an AIDS vaccine has been given a major shot in the arm with a new study that has rekindled hope ... The long thwarted dream of an AIDS vaccine has been given a major shot in the arm with a new study that has rekindled hope ... MacDonald, who has been front and centre in the global search for AIDS vaccines, did not contribute to the paper. But she says ... Wayne Koff, vice president of research at the International AIDS Vaccine Initiative and study co-author, says the paper could ...
more infohttps://www.thestar.com/life/health_wellness/2009/09/03/breakthrough_raises_hope_for_aids_vaccine.html

AIDS VACCINE FAILS TO BLOCK VIRUS - Sun SentinelAIDS VACCINE FAILS TO BLOCK VIRUS - Sun Sentinel

However, the vaccine did seem to lower the infection rate significantly among African-Americans and other non-Hispanic ... They conceded that the findings, though statistically significant, might change if the vaccine were tested among more members ... The first AIDS vaccine ever to be tested in a large number of people has failed, overall, to protect them from infection with ... totally unexpected and said they were at a loss to explain why there would be ethnic differences in response to the vaccine. ...
more infohttps://www.sun-sentinel.com/news/fl-xpm-2003-02-24-0302240065-story.html

AIDS Vaccine Quest Gets $100M InjectionAIDS Vaccine Quest Gets $100M Injection

100 million-to create an interdisciplinary institute focused on finding an AIDS vaccine, the Boston... Health News Summaries ... An AIDS vaccine? A vaccine that treats a virus? If virology ever gets to the point they can create a safe and reliable vaccine ... 100 million-to create an interdisciplinary institute focused on finding an AIDS vaccine, the Boston Globe reports. The ... Graphic shows funding for AIDS relief programs in African countries. (AP Photo) View 2 more images ...
more infohttp://www.newser.com/story/49891/aids-vaccine-quest-gets-100m-injection.html

Ten Years Later, AIDS Vaccine Search Continues - Scientific AmericanTen Years Later, AIDS Vaccine Search Continues - Scientific American

Ten Years Later, AIDS Vaccine Search Continues. Science gets closer, but a fully effective vaccine remains elusive ... a fully effective AIDS vaccine is a long way off. "There are people who will tell you we will never have a vaccine-I cant say ... But with the strides of recent years, it is no longer a question of whether we can develop an AIDS vaccine, it is simply a ... Ten years ago today, President Bill Clinton announced a national goal to develop an AIDS vaccine within a decade. At that time ...
more infohttps://www.scientificamerican.com/article/ten-years-later-aids-vaccine-search-continues/

Candidate AIDS vaccine passes key early testCandidate AIDS vaccine passes key early test

The near 40-year quest for an AIDS vaccine received a hopeful boost Saturday when scientists announced that a trial drug ... An AIDS activist lights candles placed in the shape of a red ribbon on World Aids Day in Manila on December 1, 2012 (AFP) ... Jean-Daniel Lelievre of Frances Vaccine Research Institute said the vaccine was likely not the "definitive" version, but may ... A vaccine has proven elusive as the human immunodeficiency virus (HIV) mutates easily and can hide away in cells, evading the ...
more infohttps://www.rawstory.com/2018/07/candidate-aids-vaccine-passes-key-early-test/

AIDS vaccine progress - The Columbia ChronicleAIDS vaccine progress - The Columbia Chronicle

... the incurable AIDS virus continues to destroy lives around the globe. However, a new analysis of a 2009 AIDS vaccine trial has ... However, a new analysis of a 2009 AIDS vaccine trial has brought scientists one step closer to finding a preventive. ... A]fter my experience, I would rather take my chances with no vaccine unless serious changes are made to how testing and use is ... Nelson Michael, another vaccine researcher, explained that different types of antibody responses in the body determine who gets ...
more infohttps://columbiachronicle.com/d25fe5d3-8123-534a-8bb9-3374fe9f79b4

AIDS Vaccines Show Promise After Years of Frustration | ScienceAIDS Vaccines Show Promise After Years of Frustration | Science

Jon Cohen is the author of Shots in the Dark: The Wayward Search for an AIDS Vaccine. ... CHICAGO, ILLINOIS-- The most surprising message from a major international AIDS meeting here last month is that vaccine ... Jon Cohen is the author of Shots in the Dark: The Wayward Search for an AIDS Vaccine.. ... In session after session, AIDS researchers reported results from novel vaccine experiments that have worked to various degrees ...
more infohttp://science.sciencemag.org/content/291/5509/1686

Events - IAVI - International AIDS Vaccine InitiativeEvents - IAVI - International AIDS Vaccine Initiative

... preventive HIV vaccines for use throughout the world. ... The International AIDS Vaccine Initiative (IAVI) is a global ... International AIDS Vaccine Initiative, IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc. ... 2016 International AIDS Vaccine Initiative. All rights reserved. ... HIV vaccine for Africa, with Africa #USAIDTransforms https://t. ...
more infohttp://www.iavi.org/media-center/events/eventsbyday/2018/11/6/124

Events - IAVI - International AIDS Vaccine InitiativeEvents - IAVI - International AIDS Vaccine Initiative

... preventive HIV vaccines for use throughout the world. ... The International AIDS Vaccine Initiative (IAVI) is a global ... International AIDS Vaccine Initiative, IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc. ... RT @gavi: Today, world leaders have been gathering at #WEF18 🌐👩‍💼 And were there to keep vaccines top of the agenda! 💉🔝 Watch ... 2016 International AIDS Vaccine Initiative. All rights reserved. ... New #HIV vaccine trials made the list! https://t.co/misTjFuMce ...
more infohttp://www.iavi.org/media-center/events/eventsbyday/2018/4/30/125

AIDS Vaccine Details Confirm Modest Benefit | Medpage TodayAIDS Vaccine Details Confirm Modest Benefit | Medpage Today

Detailed results of the now-famous Thai AIDS vaccine trial confirmed that the vaccine is modestly effective, but hinted that ... HIV/AIDS > HIV/AIDS AIDS Vaccine Details Confirm Modest Benefit. Detailed results of the now-famous Thai AIDS vaccine trial ... Detailed results of the now-famous Thai AIDS vaccine trial confirmed that the vaccine is modestly effective, but hinted that ... Michael and colleagues presented details of the study at the AIDS Vaccine 2009 conference in Paris, and a formal peer-reviewed ...
more infohttps://www.medpagetoday.com/hivaids/hivaids/16531

AIDS Vaccine Could Mimic Natural Immunity To HIV - Scientific AmericanAIDS Vaccine Could Mimic Natural Immunity To HIV - Scientific American

Researchers hope the natural protection could point the way to an AIDS vaccine. Steve Mirsky reports. ... AIDS Vaccine Could Mimic Natural Immunity To HIVSome individuals infected with HIV have a gene variant that keeps the virus in ... Researchers hope the natural protection could point the way to an AIDS vaccine. Steve Mirsky reports.. ... Researchers hope the natural protection could point the way to an AIDS vaccine. Steve Mirsky reports. ...
more infohttps://www.scientificamerican.com/podcast/episode/E44431DB-E7F2-99DF-3E691F52A173BA33/

VERY INNOVATIVE AIDS VACCINE | VIAV Project | FP6 | CORDIS | European CommissionVERY INNOVATIVE AIDS VACCINE | VIAV Project | FP6 | CORDIS | European Commission

VIAV is linked to the AIDS Vaccine Integrated Project (AVIP),recently awarded by the EU Commission, for future product ... The aim of VIAV is to develop a highly innovative Env-based vaccine capable of inducing cross-clade neutralizing antibodies to ... for in vitro and in vivo s tudies 3.Evaluation of the safety and immunogenicity of different Tat/Env complex-based vaccine ... prevent HIV infection.This represents the most important problem of current Env-based vaccines.VIAV aim will be achieved ...
more infohttps://cordis.europa.eu/project/rcn/74055/factsheet/en

HIV/AIDS Vaccine Trial To Be Initiated SoonHIV/AIDS Vaccine Trial To Be Initiated Soon

It has been proposed to initiate a HIV/AIDS trial in Kericho, as a collaborative work between Kenya Medical Research Institute ... The AIDS vaccine is currently being tested for its safety and efficacy on over 200 human volunteers in America and Uganda. ... Top 10 Vaccine Myths Debunked. Childhood vaccination has saved many lives, yet lots more has to be done to increase awareness ... Self-testing App in Canada may Help Early Detection of AIDS More AIDS/HIV News ...
more infohttps://www.medindia.net/news/view_news_main.asp?str=1&x=8171

Africa: The Journey Towards an Aids VaccineAfrica: The Journey Towards an Aids Vaccine

... has published a report highlighting several milestones in the journey towards an AIDS vaccine.... ... Key Correspondents] The International AIDS Vaccine Initiative (IAVI) ... Source: Vaccine - November 2, 2019. Category: Allergy & Immunology Authors: Berenson AB, Hirth JM, Southerland JH Tags: Vaccine ... Key Correspondents] The International AIDS Vaccine Initiative (IAVI) has published a report highlighting several milestones in ...
more infohttps://medworm.com/index.php?rid=142594571&cid=c_40_63_f&fid=22825&url=http%3A%2F%2Fallafrica.com%2Fstories%2F201510151590.html

AIDS vaccine trial set to start | The Scientist Magazine®AIDS vaccine trial set to start | The Scientist Magazine®

Late last week, the NIHs linkurl:AIDS Vaccine Research Subcommittee;http://www3.niaid.nih.gov/research/topics/HIV/vaccines/ ... The US government is poised to start a new AIDS vaccine trial, prompting some to caution that it is too soon to initiate such ... studies after a linkurl:Merck vaccine;http://www.the-scientist.com/blog/display/53633/ not only failed to show effectiveness ... AIDS vaccine trial set to start. The US government is poised to start a new AIDS vaccine trial, prompting some to caution that ...
more infohttps://www.the-scientist.com/?articles.view/articleNo/26471/title/AIDS-vaccine-trial-set-to-start/

U.S. Announces Decision to Test AIDS Vaccine - The New York TimesU.S. Announces Decision to Test AIDS Vaccine - The New York Times

... had also sought approval to test AIDS vaccines. Other companies are also working on potential vaccines, as are scores if not ... U.S. Announces Decision to Test AIDS Vaccine. By PHILIP M. BOFFEY and SPECIAL TO THE NEW YORK TIMES ... It will not try at this point to determine whether the vaccine is truly effective in preventing AIDS. That would require a much ... Small-scale human tests of other AIDS vaccines have already started in Zaire and France, but the new study, to be conducted ...
more infohttps://www.nytimes.com/1987/08/19/us/us-announces-decision-to-test-aids-vaccine.html

Clinical trial will test new HIV/AIDS vaccineClinical trial will test new HIV/AIDS vaccine

... vaccine_has_begun_at_brigham_and_womens_hospital_bwh_this_new_vaccine_aims_to_overcome_the_problem_of_preexisting_immunity_to_ ... common_vaccine_vectors_which_is_thought_to_be_a_major_problem_in_the_developing_world_ ... A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Womens Hospital (BWH). This new vaccine ... AIDS remains one of the worlds most devastating health problems, with an estimated 33.2 million people living with HIV/AIDS ...
more infohttp://www.biologynews.net/archives/2008/04/03/clinical_trial_will_test_new_hivaids_vaccine.html

PAR-16-028: HIV/AIDS Vaccine Scholars Program (K01)PAR-16-028: HIV/AIDS Vaccine Scholars Program (K01)

HIV/AIDS Vaccine Scholars Program (K01) PAR-16-028. ORIP ... All types of AIDS and AIDS-related applications allowed for ... are necessary for development of effective HIV/AIDS vaccines. Such NHP-based studies include both direct testing of vaccine ... The mentoring team must have at least two investigators who are active in the area of HIV/AIDS vaccine research and are ... The mentoring team can also have additional senior scientists in the area of HIV/AIDS vaccine research, as appropriate for the ...
more infohttps://grants.nih.gov/grants/guide/pa-files/PAR-16-028.html

AIDS Vaccine Research Offers New Insights On Survival | EmaxHealthAIDS Vaccine Research Offers New Insights On Survival | EmaxHealth

... to test the AIDS vaccine] scientists would be able to predict how well the vaccine would work over time." ... AIDS Vaccine and Survival. New insights into how a subpopulation of helper T-cells provides immunity and promotes survival ... "While this vaccine approach cannot actually prevent an infection, it can tamp down the AIDS virus, resulting in the development ... "Over the last decade, we have created AIDS vaccines that generate T-cell populations that can combat HIV," explains lead author ...
more infohttps://www.emaxhealth.com/53/6224.html
  • However, more than a third of those surveyed, 273 men in all, responded that they are willing both to be tested and to volunteer if they are determined not to be carrying antibodies to the AIDS virus. (latimes.com)
  • But the pair of previously unknown antibodies revealed in the paper - discovered in the blood of an unidentified African AIDS patient and known as PG9 and PG16 - appear to neutralize HIV's ability to infect its immune cell targets in almost 80 per cent of cases. (thestar.com)
  • Vaccines work by exposing the body to the disease-causing agent or a fragment of it, which primes the immune system to produce a flood of antibodies that stick to the infecting organism and block it from entering cells. (scientificamerican.com)
  • Patients whose blood contained high levels of a different antibody called IgA appeared to have less protection against HIV than their IgG-loaded counterparts, leading scientists to believe that these antibodies could play a critical role in developing an effective vaccine. (columbiachronicle.com)
  • http://www.macrovolt.com/live/dgi_053008/default.aspx According to the NIAID, the vaccine will be tested in the US on 2,400 men who have sex with other men, but trial participants must not have detectable Ad5 antibodies and must be circumcised - the two main differences in enrollment criteria from the failed Merck trial. (the-scientist.com)
  • The study will investigate only the safety of the vaccine and the degree to which it stimulates protective antibodies in the recipients. (nytimes.com)
  • Officials said the MicroGeneSys vaccine was the first to gain approval for human testing in part because the company completed the preliminary requirements first, and in part because its vaccine looked highly promising in stimulating the production of neutralizing antibodies in animal tests. (nytimes.com)
  • Such antibodies are the part of the immune system that is expected to fight off the AIDS virus. (nytimes.com)
  • Attempts to develop an HIV vaccine that triggers the production of antibodies -- the mechanism responsible for vaccine protection against other viruses including polio and hepatitis B -- have been unsuccessful. (emaxhealth.com)
  • Most vaccines depend on the induction of antibodies in our bodies to be effective, but HIV has hidden away its crown jewels, making them largely inaccessible to antibodies. (baltimoresun.com)
  • One vaccine now in human testing is based on induction of antibodies, but it is given very little hope of success. (baltimoresun.com)
  • Vaccines work through the injection of viral proteins into the body to stimulate the immune system to produce antibodies that protect cells from invading viruses like H.I.V., which causes AIDS. (nytimes.com)
  • Primate research laboratories answer HIV vaccine-related questions by testing HIV and HIV-like vaccines in chimpanzees and monkeys. (nih.gov)
  • His bottom line: At this stage, the vaccine appears to trigger the same immune system response in people that it does in newly immunized monkeys, though the volunteers have not been put to the crucial challenge of exposure to HIV. (foxnews.com)
  • In tests in 24 rhesus monkeys at Yerkes, the vaccine successfully contained a highly virulent hybrid of simian and human immunodeficiency viruses (SHIV). (emory.edu)
  • According to a Yerkes study reported in the October 2002 edition of the Journal of Virology, levels of viral DNA in the monkeys have declined to the nearly undetectable levels characteristic of a small subset of HIV-infected people, termed long-term nonprogressors, who carry HIV but do not develop AIDS. (emory.edu)
  • The vaccine was tested in hundreds of mice, guinea pigs and rabbits, as well as 12 Rhesus monkeys and 2 chimpanzees. (nytimes.com)
  • But instead of ending the experiment at this point - assuming that the vaccine conferred protection for only 100 days - Letvin and his VRC colleagues decided to follow the monkeys for an additional 750 days, a total of 850 days or nearly three years. (emaxhealth.com)
  • However, vaccines that protect monkeys against a related disease have been successful, so we believe that there must be a route to a vaccine for humans. (baltimoresun.com)
  • This study will involve 48 healthy volunteers who will receive either two or three immunizations and who will be followed to assess the safety and immunogenicity of the vaccine," explains Lindsey R. Baden, MD, Assistant Professor of Medicine at BWH and Harvard Medical School and Protocol Chair for the study. (biologynews.net)
  • Pending final approval of the trial by institutional review boards, 30 human volunteers at three sites around the country will begin receiving the vaccine within the next several months. (emory.edu)
  • The trial will compare the effects of high and low dosages of the vaccine in two groups of (HIV negative) volunteers, who will receive two intramuscular injections. (emory.edu)
  • Then the volunteers were given booster injections -- at weeks 12 and 24 -- of a second vaccine, dubbed AIDSVAX B/E, or placebo. (medpagetoday.com)
  • But seven volunteers -- five in the vaccine arm and two in the placebo arm -- were found to have been HIV-positive at the start of the study and were excluded from the main analysis, of the "modified" intent-to-treat population. (medpagetoday.com)
  • The AIDS vaccine is currently being tested for its safety and efficacy on over 200 human volunteers in America and Uganda. (medindia.net)
  • Small-scale human tests of other AIDS vaccines have already started in Zaire and France, but the new study, to be conducted with 81 volunteers who will be treated at the Clinical Center of the National Institutes of Health, in Bethesda, Md., is the first authorized in the United States. (nytimes.com)
  • A scientific team from the Johns Hopkins School of Medicine reported a year ago that the vaccine had stimulated an immune response in many of its uninfected volunteers. (baltimoresun.com)
  • The vaccine, known as Aidsvax, is made from a protein called gp120, the same protein that protrudes from the surface of HIV and helps the virus dock with cells of the body's immune system. (sun-sentinel.com)
  • After several, much-publicized vaccine failures, Koff says 'the field has basically struggled in vaccine design,' using antibody immunity. (thestar.com)
  • Action Cycling Atlanta, Inc. (ACA) was formed in 2003 by a group of cyclists who had participated in the 2002 European AIDS Vaccine Ride, one of the last AIDSRides produced by Pallotta Teamworks. (wikipedia.org)
  • In central Africa, AIDS is endemic among young heterosexuals. (latimes.com)
  • In late 2003, a Phase I clinical trial of a vaccine against clade AG, the most common HIV subtype found in West Africa, will be launched in the United States and then in Côte d'Ivoire (formerly the Ivory Coast). (emory.edu)
  • By late 2004, the Vaccine Center hopes to begin a Phase I trial of a trivalent vaccine incorporating the DNA from clades B, AG, and C. Subtype C is the most prevalent form of HIV in India and southern Africa. (emory.edu)
  • Esparza said it is imperative to conduct more vaccine trials, especially in Africa. (sun-sentinel.com)
  • I cannot emphasise how badly we need to have a vaccine… to get rid of HIV in the next generation altogether," said Francois Venter of the University of the Witwatersrand Reproductive Health and HIV Institute in South Africa. (rawstory.com)
  • Dr. David Schwartz, a Hopkins vaccine researcher, said it was important to keep the Walter Reed results in perspective. (baltimoresun.com)
  • The failed Merck Ad5 vaccine was administered in three sequential injections, with no prior DNA-based priming. (the-scientist.com)
  • Joel Blankson, who led the study, said that the role of the woman's immune system is a "good sign in terms of developing a therapeutic vaccine," which would not prevent transmission of the virus but could be used to prevent HIV-positive people from progressing to AIDS (Fox, Reuters , 8/12). (emaxhealth.com)
  • The groups also develop new adjuvant formulations and evaluate vaccine-adjuvant combinations in relevant animal models. (nih.gov)
  • Although he considers himself fortunate because he has not experienced AIDS-related symptoms since being diagnosed with HIV in 2000, Bob said the stigma of having HIV and the expensive medications he must take on a daily basis have made life more difficult. (columbiachronicle.com)
  • A vaccine has proven elusive as the human immunodeficiency virus (HIV) mutates easily and can hide away in cells, evading the immune system, only to reemerge and spread years later. (rawstory.com)
  • However, the new data suggest that when large doses are given, at least some of the vaccine survives to produce an immune reaction that could - if all works as planned - prepare the body to fight off AIDS. (foxnews.com)
  • As Dr. Lawrence K. Altman wondered earlier this year, who will test such a vaccine? (latimes.com)
  • Dr. Leon McKusick, a psychologist with the University of California at San Francisco, has surveyed 644 homosexual men about their willingness to participate in a test of an AIDS vaccine. (latimes.com)
  • The Emory Vaccine Center's Hope Clinic will serve as one of the clinical test sites for this trial. (emory.edu)
  • A spokesman for the F.D.A. said two other vaccine developers, Oncogen, a Seattle-based subsidiary of Bristol-Myers, and a team that includes the Institute for Immunologic Disorders in Houston, had also sought approval to test AIDS vaccines. (nytimes.com)
  • So even if the vaccine raises susceptibility to HIV slightly, to class that as harm in the Hippocratic sense is a stretch. (the-scientist.com)
  • With the exception of the discovery of a cure, a vaccine is the best bet in the medical rush to stop AIDS from spreading. (latimes.com)
  • Almost 30 years after its discovery, the incurable AIDS virus continues to destroy lives around the globe. (columbiachronicle.com)
  • On the other hand, a new analysis of when infections took place hints that the vaccine was most protective shortly after vaccination and then waned, but Michael said that decrease in efficacy did not reach statistical significance. (medpagetoday.com)
  • In the modified intent-to-treat population, there were 51 infections in the vaccine arm and 74 in the placebo arm, a 31.2% reduction that was significant at P =0.04. (medpagetoday.com)
  • Finally, in the smaller per-protocol population, there were 36 infections in the vaccine arm and 50 in the placebo arm. (medpagetoday.com)
  • According to the World Health Organization (WHO), in 2009 33.3 million people were living with HIV, there were 2.6 million new infections and 1.8 million AIDS-related deaths worldwide. (cnn.com)
  • SFDA officials said that they would accelerate approval process of all kinds of anti-AIDS drugs to help speed up relevant clinical researches. (chinadaily.com.cn)
  • There has been such widespread homophobia in the wake of the AIDS epidemic that it is important for the general population to appreciate that among a substantial number of homosexuals there is a strong sense of compassion and responsibility. (latimes.com)
  • Q: Because a vaccine is a long way off at best, what should countries do to minimize the impact of this epidemic? (baltimoresun.com)
  • We need a vaccine if we are going to end the epidemic. (cnn.com)
  • The Merck vaccine and several similar ones nearing human testing use a strategy called prime-boost. (foxnews.com)
  • AIDS is a peculiarly human disease. (latimes.com)
  • Chinese-developed AIDS vaccine has won government approval to be tested by human bodies, Xinhua reported Friday quoting sources with the State Food and Drug Administration (SFDA) of China. (chinadaily.com.cn)
  • One issue is safety -- the best monkey vaccine cannot be mimicked for human use. (baltimoresun.com)
  • Although AIDS (Acquired Immune Deficiency Syndrome) seems to have appeared full-blown early in this decade, it is not without analogies in the medical world. (latimes.com)
  • Dr. Smith said he also does not expect the vaccine to rid the body of HIV and free patients from the threat that they will develop and ultimately die of full-blown AIDS. (baltimoresun.com)
  • None suffered from symptoms of full-blown AIDS. (baltimoresun.com)
  • Dr. Robert Schooley, infectious-disease chief at the University of Colorado, said the vaccine's safety and immune response are 'what many of us hoped we'd be seeing when this trial started,' though he cautioned that it is still 'a long way from here to giving a vaccine that could protect people. (foxnews.com)
  • The Food and Drug Administration has approved the Emory Vaccine Center's application to begin a Phase I clinical trial of its multiprotein AIDS vaccine. (emory.edu)
  • Preliminary results from the Phase I trial of the DNA component of the vaccine should be available by the middle of next year. (emory.edu)
  • A California biotech company, ViCal, manufactured the priming components of the AIDS vaccine for the Phase I clinical trial from the DNA of clade B, the most common HIV subtype in North America and Western Europe. (emory.edu)
  • They conceded that the findings, though statistically significant, might change if the vaccine were tested among more members of minorities, who were only a small fraction of the people in the trial. (sun-sentinel.com)
  • Frahm was not part of the Thai study but presented data at the conference from the other recent large HIV vaccine study, the STEP trial. (medpagetoday.com)
  • The vaccine trial took an unconventional approach to HIV. (baltimoresun.com)
  • One other AIDS vaccine trial in the United States takes this approach. (baltimoresun.com)
  • Many people in these groups have already stopped practicing the kinds of behavior that made them especially susceptible to AIDS. (latimes.com)
  • The protein in the vaccine is made in genetically engineered hamster ovary cells. (sun-sentinel.com)
  • A]fter my experience, I would rather take my chances with no vaccine unless serious changes are made to how testing and use is regulated," Lowe said. (columbiachronicle.com)
  • New #HIV vaccine trials made the list! (iavi.org)
  • A: Actually, we do not know that a vaccine can be made. (baltimoresun.com)
  • The concept of World AIDS Vaccine Day is rooted in a May 18, 1997 commencement speech at Morgan State University made by then-President Bill Clinton. (wikipedia.org)